Enlivex Therapeutics
(NASDAQ) ENLV
Enlivex Therapeutics Financials at a Glance
Market Cap
$173.31M
Revenue (TTM)
$0.00
Net Income (TTM)
$1.24B
EPS (TTM)
$25.48
P/E Ratio
0.03
Dividend
$0.00
Beta (Volatility)
0.82 (Low)
Dividend
$0.00
Beta (Volatility)
0.82 (Low)
Price
$0.70
Volume
1,016.17
Open
$0.69
Price
$0.70
Volume
1,016.17
Open
$0.69
Previous Close
$0.72
Daily Range
$0.66 - $0.72
52-Week Range
$0.66 - $2.10
Estimated Earnings Date
Aug 24, 2026
Dividend
$0.00
Beta (Volatility)
0.82 (Low)
Price
$0.70
Volume
1,016.17
Open
$0.69
Previous Close
$0.72
Daily Range
$0.66 - $0.72
52-Week Range
$0.66 - $2.10
Estimated Earnings Date
Aug 24, 2026
ENLV News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Enlivex Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
34
CEO
Oren Hershkovitz, PhD
Website
www.enlivex.comHeadquarters
Ness Ziona, 7403618, IL
ENLV Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
126%
Return on Capital
-1%
Return on Assets
53%
Earnings Yield
33.33%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$173.31M
Shares Outstanding
241.05M
Volume
1.02K
Avg. Volume
599.70K
Financials (TTM)
Gross Profit
-$332.00K
Operating Income
-$15.00M
EBITDA
-$14.67M
Operating Cash Flow
-$10.42M
Capital Expenditure
-$68.00K
Free Cash Flow
-$10.48M
Cash & ST Invst.
$5.87M
Total Debt
$641.00K
Enlivex Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$76.00K
-111.1%
Gross Margin
0.00%
N/A
Market Cap
$173.31M
N/A
Market Cap/Employee
$2.44M
N/A
Employees
71
N/A
Net Income
$1.24B
+24115.7%
EBITDA
-$5.79M
-12.5%
Quarterly Fundamentals
Total Cash
$5.87M
-75.1%
Total Debt
$641.00K
+20.0%
Accounts Receivable
$235.00K
-82.0%
Inventory
$0.00
N/A
Long Term Debt
$383.00K
+28.1%
Short Term Debt
$258.00K
+9.8%
Return on Assets
53.10%
N/A
Return on Invested Capital
-0.65%
N/A
Free Cash Flow
-$2.91M
+29.9%
Operating Cash Flow
-$2.90M
+29.5%